Results show that various classes of antidepressants exert improving effects on cognitive function across several cognitive domains .
Specifically , studies suggest that SSRIs , the SSRE tianeptine , the SNRI duloxetine , vortioxetine and other antidepressants such as bupropion and moclobemide may exert certain improving effects on cognitive function in depression , such as in learning and memory and executive function .
The few non-pharmacological studies conducted employing cognitive orientated treatments and cognitive remediation therapy show promising results for the improvement of cognitive impairment in depression .
Cognitive dysfunction is of clinical significance and exerts longst and ing implication on patients ׳ function .
Pharmacological and non-pharmacological treatments of cognitive dysfunction are emerging .
This review evaluates pharmacological and non-pharmacological treatments of cognitive impairment primarily in the domains of memory , attention , processing speed and executive function in clinical depression .
A twelve-week randomized controlled study of the cognitive-behavioral Integrated Psychological Therapy program: positive effect on the social functioning of schizophrenic patients.
OBJECTIVES The present study was design ed to evaluate the effect of twelve weekly sessions of the cognitive-behavioral program originally known as the Integriertes Psychologisches Therapieprogramm für Schizophrene Patienten , design ated the Integrated Psychological Therapy ( IPT ) program in English , on cognition , social adjustment and quality of life in schizophrenic out patients , comparing it to the effect of treating such patients as usual . METHOD Fifty-six adult out patients ( from 18 to 65 years of age ) with ICD-10-based diagnoses of schizophrenia were r and omly assigned to two different groups : active intervention ( IPT group ) ; and treatment as usual ( control group ) . Outcome measures were quality of life ( as determined using the WHOQOL-Bref ) , cognition ( Mini-Mental State Examination and Word Recall Test ) , global functioning ( DSM-IV Global Assessment of Functioning Scale ) , social functioning ( Social and Occupational Functioning Assessment Scale ) and social adjustment ( Social Adjustment Scale ) . RESULTS The findings suggest that , in comparison with treatment as usual ( control group ) , the twelve-session IPT program had a positive effect on several outcome measures : cognition in the domains of spatiotemporal orientation ( p = 0.051 ) and memory ( p = 0.031 ) ; overall social adjustment ( p = 0.037 ) , leisure/social life ( p = 0.051 ) and family relations ( p = 0.008 ) ; overall functioning ( p = 0.000 ) ; social-occupational functioning ( p = 0.000 ) ; and quality of life in the psychological domain ( p = 0.021 ) . CONCLUSIONS The twelve-session cognitive-behavioral IPT intervention demonstrated superiority over treatment as usual in its effects on cognition , social adjustment and quality of life . Studies involving larger sample s , longer follow-up periods and additional outcome measures are needed in order to assess the specific effects on dimensions of social functioning , cognitive functioning and quality of life in patients with schizophrenia
Results show that various classes of antidepressants exert improving effects on cognitive function across several cognitive domains .
Specifically , studies suggest that SSRIs , the SSRE tianeptine , the SNRI duloxetine , vortioxetine and other antidepressants such as bupropion and moclobemide may exert certain improving effects on cognitive function in depression , such as in learning and memory and executive function .
The few non-pharmacological studies conducted employing cognitive orientated treatments and cognitive remediation therapy show promising results for the improvement of cognitive impairment in depression .
Cognitive dysfunction is of clinical significance and exerts longst and ing implication on patients ׳ function .
Pharmacological and non-pharmacological treatments of cognitive dysfunction are emerging .
This review evaluates pharmacological and non-pharmacological treatments of cognitive impairment primarily in the domains of memory , attention , processing speed and executive function in clinical depression .